RecruitingPhase 3NCT07190196
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
Studying IgG4-related disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sanofi
- Intervention
- Rilzabrutinib(drug)
- Enrollment
- 124 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2030
Study locations (30)
- San Jose Clinical Trials- Site Number : 8400016, San Jose, California, United States
- Solace Clinical Research - Tustin- Site Number : 8400020, Tustin, California, United States
- Life Clinical Trials - Margate - Colonial Drive- Site Number : 8400002, Margate, Florida, United States
- Schiff Center for Liver Diseases/University of Miami- Site Number : 8400010, Miami, Florida, United States
- Vitalia Medical Research - Margate- Site Number : 8400025, Palm Beach Gardens, Florida, United States
- Primeway Clinical Research- Site Number : 8400019, Fayetteville, Georgia, United States
- Mayo Clinic in Rochester - Minnesota- Site Number : 8400017, Rochester, Minnesota, United States
- Cleveland Clinic - Cleveland- Site Number : 8400001, Cleveland, Ohio, United States
- Paramount Medical Research and Consulting LLC- Site Number : 8400018, Middleburg Heights, Ohio, United States
- Stryde Research- Site Number : 8400011, Plano, Texas, United States
- Epic Medical Research - Red Oak- Site Number : 8400003, Red Oak, Texas, United States
- Digestive Health Research of North Texas- Site Number : 8400021, Wichita Falls, Texas, United States
- Velocity Clinical Research - Seattle- Site Number : 8400005, Seattle, Washington, United States
- Investigational Site Number : 0320005, Berazategui, Buenos Aires, Argentina
- Investigational Site Number : 0320002, Resistencia, Chaco Province, Argentina
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07190196 on ClinicalTrials.govOther trials for IgG4-related disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07061938Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related DiseaseAcepodia Biotech, Inc.
- RECRUITINGPHASE2NCT07025330A Study of Efgartigimod in Patients With IgG4-Related DiseaseStanford University
- RECRUITINGPHASE2NCT07148791Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related DiseaseChinese PLA General Hospital
- RECRUITINGPHASE2, PHASE3NCT07068165A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related DiseasePeking Union Medical College Hospital
- RECRUITINGNANCT07104058A Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RDLuo Yaping
- ACTIVE NOT RECRUITINGNCT06844864Adaptive and Trained Immunity in the Pathogenesis of IgG4-Related DiseaseIRCCS San Raffaele
- RECRUITINGEARLY PHASE1NCT06497387Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related DiseaseTongji Hospital
- RECRUITINGEARLY PHASE1NCT06497361Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related DiseaseTongji Hospital